Predictive Oncology will raise $344.4 million to launch the ATH Token treasury strategy.

On September 29, Predictive Oncology Inc. (NASDAQ: POAI), a medical device company, announced today that it has priced two private placement financing transactions to support the implementation of its digital asset portfolio strategy, with the core holding asset being the native functional Token ATH of the Aethir ecosystem. The company will raise approximately $344.4 million through two public company private investment (PIPE) financings for the purchase and sale of common stock and pre-funded warrants: Cash PIPE: The company will issue approximately 66.7 million shares of common stock (or common stock equivalents via pre-funded warrants) at an issuance price of $0.7751 per share, with total cash gross proceeds of approximately $51.7 million. Crypto PIPE: The company will issue up to 223.6 million pre-funded warrants, each priced at the issuance price minus $0.01, in exchange for approximately $292.7 million notional value, equivalent to approximately $173.3 million discount value, structured as both Lock-up Position and non-lock-up Aethir Tokens as physical contributions. The pre-funded warrants in the Crypto PIPE will be immediately exercisable upon the company's receipt of shareholder approval. The two PIPEs are expected to close simultaneously around October 2, 2025, subject to the satisfaction of customary closing conditions. The company plans to use the physical contributions of Aethir (ATH) to implement the digital asset portfolio strategy and to utilize the remaining net proceeds from the PIPE primarily to acquire ATH in the open market to further support this strategy, while also using it for working capital and general corporate purposes.